ArticleiScience2024
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perovskites are extensively studied in scintillation detection due to their low cost, simple synthesis, high scintillation light yield, and rapid decay times. However, their instability to light and radiation leads to scintillation performance degradation. To address these stability concerns, this paper proposes a new perovskite nanocrystal (NC) synthesis method that employs aminopropyllsobutyl polyhedral oligomeric silsesquioxane (POSS) as a ligand and a coating layer to passivate the perovskite NCs, significantly enhancing their stability and photoluminescence efficiency. Furthermore, the resultant perovskite/aminopropyllsobutyl POSS nanocomposites exhibit remarkable capabilities in X-ray detection limits, imaging quality, and radiation hardness. These findings underscore the potential of enhanced perovskite in revolutionizing the field of scintillator materials, offering promising pathways for their future applications and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.